Skip to content
S6084Senate2023-2024 SessionSame asA6506

Ban Xylazine Sales

Official title

“Prohibits the sale of xylazine”

Status
In Senate Committee
Consumer Protection
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Consumer Protection

What's happening

This bill prohibits the sale of xylazine in New York except for verified institutional, veterinary, or scientific use, with penalties for violations.

Why it matters

  1. Targets illicit diversion and misuse. By restricting xylazine sales to only those with verifiable institutional, veterinary, or scientific intent, the bill aims to curb the growing problem of xylazine being used as an adulterant in street drugs or for other unsafe purposes.

  2. Requires robust recordkeeping. Businesses must collect and retain documentation of both the buyer’s age and the intended use, increasing accountability and creating a paper trail that could help law enforcement track suspicious transactions.

  3. Directs penalties to public health efforts. Civil penalties for violations are funneled specifically into New York’s drug treatment and public education fund, ensuring that enforcement generates resources for addressing substance abuse and community awareness.

  4. Explicitly bans access by young people. The prohibition of any xylazine sales to individuals under 21 adds a layer of youth protection and aligns with broader efforts to restrict access to potentially dangerous substances among minors.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Xylazine sellers and online platforms

    Businesses would have to retain sales records and proof of purchasers’ age and intended use, with civil penalties for violations.

  • Veterinary, scientific and institutional purchasers

    Buyers would need to provide proof that xylazine is intended for one of these permitted purposes.

  • People under 21

    Businesses would be prohibited from knowingly selling, offering for sale or delivering xylazine to them.

  • New York attorney general

    The office would be authorized to recover civil penalties, with proceeds directed to the New York state drug treatment and public education fund.

Headline styles

Ban Xylazine Sales

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Nathalia Fernandez

Senator · Senate District 34

Chair, Alcoholism And Substance Use Disorders

History

  1. Print number 6084b
  2. Amend and recommit to consumer protection
  3. Referred to consumer protection
  4. Print number 6084a
  5. Amend and recommit to consumer protection
  6. Referred to consumer protection

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A6506Assembly

Ban Xylazine Sales

In Senate Committee · Consumer Protection · Sponsor Yudelka Tapia

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

6084--B

2023-2024 Regular Sessions

IN SENATE

March 28, 2023

Introduced by Sens. FERNANDEZ, ADDABBO -- read twice and ordered printed, and when printed to be committed to the Committee on Consumer Protection -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- recommitted to the Committee on Consumer Protection in accordance with Senate Rule 6, sec. 8 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the general business law, in relation to prohibiting the sale of xylazine

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The general business law is amended by adding a new section 392-k to read as follows:

§ 392-k. Sale of xylazine. 1. For purposes of this section, the term "xylazine" shall mean a pharmaceutical drug used for sedation, anesthesia, muscle relaxation, and analgesia in animals such as horses, cattle, and other non-human mammals.

2. No corporation, partnership, limited liability company, firm, online platform, or any other business entity doing business within this state shall knowingly sell, offer for sale, or deliver xylazine to individuals without proof of its intended use for institutional, veterinary, or scientific purposes.

3. No corporation, partnership, limited liability company, firm, online platform, or other business entity doing business within this state shall knowingly sell, offer for sale, or deliver xylazine to individuals under the age of twenty-one.

4. Any corporation, partnership, limited liability company, firm, online platform or other business entity doing business within this state which knowingly sells, offers for sale, or distributes xylazine, shall require and retain sales records, proof of age, and proof of use from all purchasers.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD10463-06-4

5. Any corporation, partnership, limited liability company, firm, online platform, or other business entity doing business within this state that violates the provisions of this section by knowingly selling, offering for sale, or delivering xylazine shall be subject to a civil penalty of not more than three thousand dollars for a first violation, and sixty-five hundred dollars for each subsequent violation, recoverable in an action by the attorney general of the state of New York. All funds collected or received by the state from civil penalties imposed under this section shall be deposited in the New York state drug treatment and public education fund established pursuant to section ninetynine-jj of the state finance law.

§ 2. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the general business law, in relation to prohibiting the sale of xylazine

Purpose or general idea of bill

To prohibit the sale of xylazine without proof of its intended use for institutional or scientific purposes.

Summary of provisions

Section 1 prohibits the sale and delivery of xylazine in the State with- out proof of its intended use for institutional or scientific purposes.

Section 2 sets the effective date.

Justification

We are facing an opioid epidemic of historic levels in the State of New York. Outcomes for individuals are worsening as additives such as fenta- nyl and xylazine are being added to the formula. Unlike fentanyl, the effects of which can be reversed with opioid antagonists like naloxone, xylazine is a tranquilizer with no equivalent reversal agent. Further- more, xylazine can cause not only death but many other complications including unconsciousness and open sores.

We need to be proactive and prevent xylazine from being added to opioids being sold on the street to avoid the devastating effects we have seen in other parts of the country. This bill would prohibit the sale of xylazine in person or online without proof that the buyer is using it for its intended use, thus adding some control over the sale and ship- ment of xylazine in our state.

Prior legislative history

New bill

Fiscal implications

TBD

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.